Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The company filed an NT on the 29th so somewhere on around 12 January we should have an annual report!
I don’t know if there was any funds collected so I am not expecting to see revenue in this report. But I am expecting to see revenue on the next quarterly report!
How old is this news
I sent you a message on Twitter : Mike is a excellent writer with knowledge of science and drugs. He has been contacted to produce articles for a number of biotechs.
I have looked into BIXT the massive number of papers the CEO Dr Platt has written on Galectin and viruses!
Over 30 years of he career! BIXT is not the first company he has founded! Do your own DD ! BIXT is going to make medical history!
Right! LIACF 2024 3$ options!
So what happens to them.
PLUUF was the company that owned the uranium mine!
Getting some action on Qrons today!
12/14/22. New Pre-clinical Research program was announced !
Can someone please tell me What happens to the options shareholders receive from PLUUF merger?
What happens to the options shareholders receive from PLUUF merger?
https://drive.google.com/file/d/1jzqUNg_4rXx2lySBPQF1C7G_u-8N4jbu/view?usp=share_link
Share this with everyone!
BOSTON, MASSACHUSETTS, Dec. 08, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and other viral diseases, announced the receipt of an Investigational New Drug (IND) authorization letter from India’s Central Drugs Standard Control Organization (CDSCO) to optimize dosage in Covid-19 patients. The trial’s objective is to provide guidance for a 408 patient Phase III trial.
About Bioxytran, Inc.
Bioxytran, Inc. is a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The leading drug candidate, ProLectin-M, is a new class of antiviral drug designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant diseases. Bioxytran’s other development programs are for pulmonary fibrosis and stroke treatment. More information can be found at www.bioxytraninc.com
Investor Relations
Michael Sheikh
509-991-0245
mike.sheikh@bioxytraninc.com
Forward-Looking Statements
This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran’s actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.
Primary Logo
Source: BIOXYTRAN, INC.
December 8th, 2010: I was in this stock:
SmartMetric Announces Today That It Has Filed a Patent Infringement Lawsuit Against American Express and Will Be Seeking Financial Compensation Amongst Other Things Against the Defendant for Its Patent Infringement
20% gain in the stock! My suggestion take the money and run! Take the money and run!
Did y’all see the press release!?
The card is nearing completion.
I understand market has been a challenge!
I have a lot of faith in the management of this company to do the right thing!
I think it should be ready for world wide distribution in about another 10 or 12 years!
I think there were 29M shares when I first got in this stock. Now there is over 905M shares
I want thinking we would make a new 52 week low today! Well there’s always tomorrow!
$CYCA Cytta Corp: huge volume day! Might be highest volume day in a couple months! I think it may very well be the anticipation of the news of the dividend spinoff of the subsidiary that has created this volume and nearly a 25% gain in the stock today!
$CYCA Cytta Corp: huge volume day! Might be highest volume day in a couple months! I think it may very well be the anticipation of the news of the dividend spinoff of the subsidiary that has created this volume and nearly a 25% gain in the stock today!
IMHO I think these low stock prices are a great buy!
This was great news! Getting recognition !
https://www.otcmarkets.com/stock/BIXT/news/Bioxytran-Inc-Announces-the-Reinitiation-of-Coverage-of-Its-Stock-by-Avise-Analytics?id=381233
Yes, I agree, And could be the treatment for many other viruses
My thoughts are they are working on the dividend spinoff
Cyca have an annual report coming next! Last years 10K was filed in January for 9/30. And the 1st quarter results were filed the next month in Feb .
So we are not going to see sales until that 10Q in Feb.
Strongly advise everyone
How can they be testing a card that does not exist? Buy chips for a card that does not exist?
News out!
Sounds a bit misleading. How much of this grant did they actually get? Like the last one. It was stated the entire amount but in reality it was divided with other recipients
SMME is sitting on the all time low of 0.0009!
This is great news!
There are numerous viruses that this drug or a modification of this drug might be successful with treatments or cures!
And then lied, stating SMME won the case when in fact the court ruled against them!
As far as I can see there are currently 3 IGAN 2.0 systems out working!
Also there will be another adventure into SA to see the river turtles egg hatching this month!
Price has been falling since late September. Hopefully who ever is selling will stop.
Meanwhile the spin-off will be done within the next 8 weeks !
I have a fidelity account my orders show up in level 2 GTSM!
OTCX is the one I worry about
They always stay ahead as best bid price. I change my order, they up it better !
Like right now I am .0833 they are .0834. I’ve changed my order 3 times
The 52 week low is 0.0009! I am expecting this to be taken out and go lower!
Yep saw the news! Heard it all before!